-       Report 
   - June 2025
    -  81 Pages 
    
   From       €3101EUR$3,450USD£2,720GBP 
                -       Report 
   - February 2024
    -  95 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - January 2024
    -  112 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                  -       Report 
   - August 2024
    -  92 Pages 
    China
   
   From       €1618EUR$1,800USD£1,419GBP 
                 -       Report 
   - August 2024
    -  214 Pages 
    China
   
   From       €3595EUR$4,000USD£3,153GBP 
                        Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive    market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less   Read more